Catalyst ligands

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.112881-51-3,4′-(4-Pyridyl)-2,2′:6′,2”-terpyridine,as a common compound, the synthetic route is as follows.

The ligand Ptpy (pyridine terpyridine) was synthesised according to known procedures which involve the Kronke pyridine synthesis. A warm methanolic solution of Ptpy (0.310 g, 1 mM) was added to a MeOH solution of CuCl2¡¤2H2O (0.171 g, 1 mM) and kept for stirring for 3 h. A green precipitate was obtained in quantitative yield. After filtration the green precipitate was dissolved in methanol: acetonitrile (1:1) solution and heated to boil and kept aside for crystallization. Needle shaped crystals suitable for X-ray diffraction was obtained. Yield 86%. Elemental analysis data for C20H17Cl3CuN4O[Cu(Ptpy)(Cl)2]¡¤H2O¡¤Cl, calcd (%): C 48.11, H 3.43, N 11.22; found (%) C 47.93, H 3.32, N 11.16. ESI-MS m/z, found: 408.13(100%); calcd: [Cu63(Ptpy)(Cl)+] 408.76., 112881-51-3

112881-51-3 4′-(4-Pyridyl)-2,2′:6′,2”-terpyridine 11438308, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Manikandamathavan, Verasuntharam M.; Rajapandian, Varatharaj; Freddy, Allen J.; Weyhermueller, Thomas; Subramanian, Venkatesan; Nair, Balachandran Unni; European Journal of Medicinal Chemistry; vol. 57; (2012); p. 449 – 458;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

485-71-2,With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.485-71-2,Cinchonidine,as a common compound, the synthetic route is as follows.

General procedure: A mixture of (-)-cinchonidine (1.0 mmol) and benzyl bromide 3 (1.0 mmol) having sulfonamidegroup was stirred in DMF (4 mL) at 25 C for 20 h. After the reaction was completed, the reaction mixture was added dropwise to ether (50mL) with stirring. The solid precipitated was filtered,washed with ether (20 mL) and hexane (20 mL) to afford cinchonidinium salt 5

485-71-2 Cinchonidine 101744, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Itsuno, Shinichi; Yamamoto, Shunya; Takata, Shohei; Tetrahedron Letters; vol. 55; 44; (2014); p. 6117 – 6120;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

17217-57-1, 4,4′-Dimethoxy-2,2′-bipyridine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: All the solvents used in this work were of reagent quality and usedwithout further purification. Lapachol was obtained according to theprocedure described in [24]. The precursors cis-[RuCl2(PPh3)2(X-bipy)](X = H, methyl (Me) and methoxy (MeO)) and cis-[RuCl2(PPh3)2(phen)] were prepared according to literature [26,27]. Typically[100.0 mg; 0.1 mmol] of the [RuCl2(PPh3)3] was dissolved in degassed20 mL of dichloromethane (Merck) and N-heterocyclic (X-bipy or phen) [22.0 mg; 0.11 mmol] ligand was added. The reaction mixturewas stirred for 30 min at room temperature and the volume of theresulting blue solution was reduced, under vacuum, to ca. 2 mL anddiethyl ether (Merck) was then added to precipitate a red solid, whichwas filtered off, washed several times with diethyl ether, and driedunder vacuum. Yield: ~78 mg (80?90percent)., 17217-57-1

17217-57-1 4,4′-Dimethoxy-2,2′-bipyridine 2733927, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Barbosa, Marilia I.F.; Correa, Rodrigo S.; De Oliveira, Katia Mara; Rodrigues, Claudia; Ellena, Javier; Nascimento, Otaciro R.; Rocha, Vinicius P.C.; Nonato, Fabiana R.; Macedo, Tais S.; Barbosa-Filho, Jose Maria; Soares, Milena B.P.; Batista, Alzir A.; Journal of Inorganic Biochemistry; vol. 136; (2014); p. 33 – 39;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.62937-45-5,D-Prolinamide,as a common compound, the synthetic route is as follows.

62937-45-5, A solution of 5-(4-chlorophenyl)-2-{ [l-(4-chloropyridin-3-yl) H-l,2,4-triazol-3-yl]methyl}-4- [(2S)-3,3,3-trifluoro-2-hydroxypropyl]-2,4-dihydro-3H-l,2,4-triazol-3-one (Example 6A, 150 mg, 300 muiotaetaomicron) in ethanol (600 mu) was treated with D-prolinamide (342 mg, 3.00 mmol) and heated at reflux overnight. The reaction mixture was purified by preparative HPLC (Method 4) affording 137 mg (79 % of th.) of the title compound. LC-MS (Method 2): Rt = 1.03 min; MS (ESIpos): m/z = 578.2 [M+H]+ -NMR (400 MHz, DMSO-d6) delta [ppm]: 8.73 (s, 1H), 8.27-8.00 (m, 2H), 7.80-7.50 (m, 4H), 7.30 (s, 1H), 7.10 (s, 1H), 6.91 (d, 1H), 6.52 (d, 1H), 5.19-4.99 (m, 2H), 4.40-4.20 (br m, 1H), 4.16-3.76 (m, 3H), 2.93-2.66 (m, 2H), 2.11-1.91 (m, 1H), 1.85-1.44 (m, 3H).

The synthetic route of 62937-45-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; BAYER AKTIENGESELLSCHAFT; BAYER PHARMA AKTIENGESELLSCHAFT; COLLIN-KROePELIN, Marie-Pierre; KOLKHOF, Peter; NEUBAUER, Thomas; FUeRSTNER, Chantal; POOK, Elisabeth; WITTWER, Matthias, Beat; LUSTIG, Klemens; TINEL, Hanna; LINDNER, Niels; SCHIRMER, Heiko; (449 pag.)WO2019/81307; (2019); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.135616-40-9,(R,R)-(-)-N,N’-Bis(3,5-di-tert-butylsalicylidene)-1,2-cyclohexanediamine,as a common compound, the synthetic route is as follows.

5,46 G (0,01 mol) (R, R)-2, 2′- [1, 2-Cyclohexandiyl) bis (nitrilomethylidyn)] bis [4,6-di- tert.-butyl)-phenol] (Illa) werden in 25 ml THF vorgelegt und mit 1,26 g (0,005 mol) VANADYLSULFAT-PENTAHYDRAT in 25 ml Ethanol versetzt. Nach drei Stunden unter Rueckfluss wird das Loesungsmittel abdestilliert, der Rueckstand in 50 mi Dichlormethan aufgenommen und die Loesung mit 300 ml Wasser gewaschen. Nach Phasentrennung, Trocknen der Loesung mit Natriumsulfat und Abdestillieren des Loesungsmittels erhaelt man 3,6 g gruenes, amorphes Pulver. Zusammensetzung des Gemischs nach HPLC (Gew. -%) : Komponente (I) : (II) : (III) =43% : 13% : 44 %.

135616-40-9, 135616-40-9 (R,R)-(-)-N,N’-Bis(3,5-di-tert-butylsalicylidene)-1,2-cyclohexanediamine 2733339, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; CLARIANT GMBH; WO2004/55028; (2004); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

62937-45-5,62937-45-5, D-Prolinamide is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: A stirred suspension of 2-chloro-N-(1-methyl-1H-imidazol-4-yl)furo[3,2-d]pyrimidin-4-amine (1b) (100 mg, 0.40 mmol), (S)-pyrrolidin-2-ylmethanol (122 mg, 1.20 mmol) in N-Methyl-2-pyrrolidinone (1 mL) was subjected to microwave irradiation at 150 C for 2 h. The reaction mixture was diluted with ethyl acetate (50 mL), washed with brine (2 x 20 mL), dried, filtered and concentrated in vacuum. The crude residue was purified by combiflash (silica gel, 12 g, eluting with chloroform/CMA-80) to afford (S)-(1-(4-((1-methyl-1H-imidazol-4-yl)amino)furo[3,2-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (2a) (43 mg, 34 % yield) as a light yellow solid; NMR (300 MHz, DMSO-i) delta 9.90 (s, 1H, D20 exchangeable), 8.00 (d, J = 2.1 Hz, 1H), 7.44 (s, 1H), 7.42 (d, J = 1.4 Hz, 1H), 6.71 (d, J = 2.1 Hz, 1H), 4.94 (s, 1H, D2O exchangeable), 4.13 (s, 1H), 3.83 – 3.69 (m, 1H), 3.64 (s, 3H), 3.62 – 3.49 (m, 1H), 3.48 – 3.23 (m, 2H), 2.07 – 1.83 (m, 4H); MS (ES+): 315.4 (M+l), 337.5 (M+Na), (ES-): 313.4 (M- 1). HPLC purity: 98.70%.

62937-45-5 D-Prolinamide 447554, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; BIOCRYST PHARMACEUTICALS, INC.; KOTIAN, Pravin, L.; BABU, Yarlagadda, S.; KUMAR, V., Satish; ZHANG, Weihe; LU, Peng-Cheng; RAMAN, Krishnan; (747 pag.)WO2018/232094; (2018); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.3779-42-8,3-Bromo-N,N,N-trimethylpropan-1-aminium bromide,as a common compound, the synthetic route is as follows.

COMPOUND 6; 5-[3,5-bis-(3-Trimethyla?imoiiio-prop3doxy)-phenyl3-15-undecyl- porphyrin dichloride; To a vigorously-stirred suspension of Compound 5 (80 mg, 0.14 mmol) and K2CO3 (230 mg, 1.7 mmol) in DMF (30 mL) is added (1- bromopropyl)-trimethylammomum bromide (0.3 g, 16.6 mmol) at 50 0C. The mixture is stirred at this temperature for 18 h. After removal of the DMF under reduced pressure, the residue obtained is dissolved in methanol (5 mL) and filtered through a pad of silica gel (depth 2 cm) supported on a steel frit (diameter 3.5 cm). After washing the pad with methanol (ca. IL) the crude product is eluted with acetic acidrmethanol .-water (3:2:1, by vol.). Appropriate fractions are collected and, after evaporation of the solvent under reduced pressure, the residue obtained is purified by chromatography on a column (2.5 x 40 cm) of Sephadex LH-20 eluting with n-butanol:water:acetic acid (5:4:1, by vol., upper phase). After removal of the solvent from appropriate fractions under reduced pressure, the residue obtained is dissolved in methanol (5 mL) and the solution is passed through a short column (3.5 x 20 cm) of anion exchange resin (Amberlite IRA 400, chloride form). After collection of the eluate, solvent is removed under reduced pressure and the residue obtained is dried under high vacuum to yield the dichloride salt as a violet solid.1H-NMR: deltaH (300Mz, CD3OD): 0.75 (t, 3J l.5 Hz, 3 H), 1.05-1.20 (m, 14 H), 1.45- 1.50 (m, 2 H), 2.05-2.15 (m, 4 H), 2.15-2.20 (m, 2 H)5 2.95 (s, 18 H), 3.35-3.45 (m, 4 H), 3.95 (t, 3J 7.5 Hz, 4 H), 4.55 (t, 3J 7.5 Hz, 2 H), 6.85 (m, 1 H)5 7.35 (m, 2 H), 8.85-8.90, 9.15-9.20, (3 x m, 8 H), 10.10 (s, 2 H)., 3779-42-8

As the paragraph descriping shows that 3779-42-8 is playing an increasingly important role.

Reference£º
Patent; DESTINY PHARMA LIMITED; WO2006/765; (2006); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

787-70-2, [1,1′-Biphenyl]-4,4′-dicarboxylic acid is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated,787-70-2

General procedure: A mixture of acid (0.2 mmol), alcohol (0.6 mmol) and GO (50 wt%, calculated with the mass of acid) in ethyl alcohol or DCE (1 mL) was placed in a test tube equipped with a magnetic stirring bar. The mixture was stirred at 100 C for 24 h. After the reaction was finished, filtered the GO, solvent was removed, and the residue was separated by column chromatography to give the pure sample.

The synthetic route of 787-70-2 has been constantly updated, and we look forward to future research findings.

Reference£º
Letter; Chen, Zhengwang; Wen, Yuelu; Fu, Yejuan; Chen, Hai; Ye, Min; Luo, Guotian; Synlett; vol. 28; 8; (2017); p. 981 – 985;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.51094-17-8,4,4′,4”,4”’-(21H,23H-porphine-5,10,15,20-tetrayl)tetrakis-Phenol,as a common compound, the synthetic route is as follows.,51094-17-8

COMPOUND 1; 5,10,15,20-tetralds-[4-(3-Trimeth34ammonio-propyloxy)-phenyl]- porphyrin tetrachloride; To a vigorously-stirred suspension of 5,10,15,20-tetrakis-(4-hydroxy- phenyl)-porphyrin (50 mg, 0.07 mmol) and K2CO3 (230 mg, 1.7 mmol) in DMF (20 mL), a solution of (l-bromopropyl)-trimethylammonium bromide (0.27 g, 1.05 mmol) in DMF (5 mL) is added dropwise at 5O0C during 30 mins. The mixture is stirred at 5O0C for 15 h. After removal of DMF under reduced pressure, the residue obtained is dissolved in methanol (5 mL) and filtered through a pad of silica gel (depth 2 cm) supported on a steel frit (diameter 3.5 cm). After washing with methanol (1 L), the pad is eluted with acetic acid. After evaporation of solvent from the eluate, the residue obtained is purified by chromatography on a column (2.5 x 40 cm) of Sephadex LH20 eluting with n- butanol: water: acetic acid (4:5:1, by vol., upper phase). The recovered material is dissolved in the minimum volume of methanol and the solution is passed through a short column (3.5 x 20 cm) of anion exchange resin (Amberlite IRA 40O5 chloride form). The recovered tetrachloride salt is dried under high vacuum and obtained as a violet solid. 1H-NMR: deltaH (300MHz, CD3OD): 2.35-2.50 (bs. 8 H), 3.25-3.35 (bs, 36 H), 3.65- 3.75 (bs, 8 H), 4.35 (m, 8 H), 7.30, 8.10 (2 x d, 3J 8.5 Hz, 16 H), 8.80- 9.00 (bs, 8 H).

51094-17-8 4,4′,4”,4”’-(21H,23H-porphine-5,10,15,20-tetrayl)tetrakis-Phenol 135438030, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; DESTINY PHARMA LIMITED; WO2006/765; (2006); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

168646-54-6, 5,6-Diamino-1,10-phenanthroline is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: The respective diketo compound and 1, 10-phenanthroline-5, 6-diamine were dissolved in methanol followed by catalytic amountof acetic acid and the mixture was refluxed for 5-6 h. The mixturewas cooled to room temperature and the solid separated wasfiltered, washed with small amount of cold methanol followed byhexane and dried well to get red colored product.

168646-54-6, The synthetic route of 168646-54-6 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Kothavale, Shantaram; Sekar, Nagaiyan; Dyes and Pigments; vol. 136; (2017); p. 31 – 45;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI